As we begin a new year, we are excited to share TrialNet’s progress in 2025 and our plans for the year ahead.

We also want to take this opportunity to thank our participants, their families, and our research teams. Your commitment helps us learn more about how T1D progresses and contributes to advances in preventing and delaying type 1 diabetes (T1D).

Completed enrollment for two clinical studies testing new therapies for the first time in T1D

In 2025, we reached enrollment goals for two TrialNet studies testing immune therapies in people recently diagnosed with T1D.

• T1D RELAY is testing rituximab-pvvr followed by abatacept to learn if the combination can preserve insulin production.
• JAKPOT T1D is testing two Janus kinase (JAK) inhibitors to see if either or both can preserve insulin production.

Both studies are on track to meet their projected milestones, and JAKPOT T1D will wrap up its treatment phase by the end of this year.

What we learn from new onset studies informs additional research in earlier stages of the disease before clinical diagnosis.

Launched two new programs to increase community involvement

In 2025, TrialNet created the Community Advisory Board (CAB) to amplify the voices of people impacted by T1D in our research. More than 20 CAB members are providing insights to help shape study design and execution, recruitment strategies, and how results are shared. This additional community participation helps ensure that TrialNet research is accessible and understandable to everyone we serve. Learn more here.

TrialNet’s new Ambassador Program provides the opportunity to play an important role in advancing TrialNet research. Anyone can become a TrialNet Ambassador. Using a toolkit provided by TrialNet, Ambassadors inform and engage family, friends and social media followers about TrialNet screening, clinical trials and discoveries. Learn more here.

2025 Highlights

• Screened more than 10,000 people for the early stages of T1D for the second year in a row, bringing the total number of people screened by TrialNet to more than a quarter million.
• Offered TrialNet screening at dozens of community events for families impacted by T1D.
• Reached enrollment goals for two studies: T1D RELAY and JAKPOT T1D. Both studies are testing immune therapies aiming to preserve insulin production in people newly diagnosed with T1D.
• Continued to offer the Long-term Investigative Follow-Up in TrialNet Study (LIFT) to prevention study participants who develop T1D, as well as to participants in studies for people newly diagnosed when their initial study ends.
• Expanded the TrialNet network with three Clinical Centers: University of Utah, University of Miami, and University of South Florida.
• Published more than 20 scientific articles in peer-reviewed journals.
• Launched a Community Advisory Board to amplify the voices of people impacted by T1D in TrialNet research.
• Launched the TrialNet Ambassador Program to empower advocates of T1D research.

2026: Key initiatives for the year ahead

TrialNet Chair, Kevan Herold, MD, Yale University, reminds us, “While we have made significant progress, there is much more work to be done. With T1D diagnoses projected to continue to rise globally, our work is of paramount importance. We are excited to enter into a new era of trials that not only test safe and effective drugs and novel designs at every stage of the disease but are developed by emerging leaders and in direct partnership with members of the T1D community.”

TrialNet’s top initiatives for 2026 include:

The RESET T1D Study will soon begin enrolling people newly diagnosed with T1D. This study is testing rezpegaldesleukin to see if it can prolong insulin production by stimulating regulatory T cells to restore immune balance. Rezpegaldesleukin is already being studied in people with other autoimmune diseases, such as psoriasis and eczema. This is the first time it is being studied in people with TID.

Our pipeline includes new clinical trial designs focused on stopping progression of T1D in its early stages, before clinical diagnosis, with improved efficiency.

Our Community Advisory Board will continue to provide feedback on every new study in development to better inform our research and make it easier to participate in clinical trials.

Join us on our mission to stop T1D!

Get screened

If you have a relative with T1D, you may be eligible for free risk screening that can detect the early stages of T1D years before symptoms appear. Learn more here.

Positive for autoantibodies?

If you’ve been screened outside of TrialNet and tested positive for autoantibodies, you can still contribute to T1D research. Confirm your findings with TrialNet rescreening, and we will let you know if you’re eligible to participate in any of our clinical trials. Learn more about rescreening here.

Become a TrialNet Ambassador

With our Ambassador Toolkit, you’ll have all the resources you need to inform your friends, family, and followers about TrialNet. Learn more here.

Follow us on social media

Everyone can help advance T1D research by sharing TrialNet social media posts. To stay up to date by following us on Facebook, Instagram, and X.